BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 17967830)

  • 1. B lymphocyte stimulator expression in patients with rheumatoid arthritis treated with tumour necrosis factor alpha antagonists: differential effects between good and poor clinical responders.
    La DT; Collins CE; Yang HT; Migone TS; Stohl W
    Ann Rheum Dis; 2008 Aug; 67(8):1132-8. PubMed ID: 17967830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B lymphocyte stimulator expression in pediatric systemic lupus erythematosus and juvenile idiopathic arthritis patients.
    Hong SD; Reiff A; Yang HT; Migone TS; Ward CD; Marzan K; Shaham B; Phei WC; Garza J; Bernstein B; Stohl W
    Arthritis Rheum; 2009 Nov; 60(11):3400-9. PubMed ID: 19877053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab.
    Sekiguchi N; Kawauchi S; Furuya T; Inaba N; Matsuda K; Ando S; Ogasawara M; Aburatani H; Kameda H; Amano K; Abe T; Ito S; Takeuchi T
    Rheumatology (Oxford); 2008 Jun; 47(6):780-8. PubMed ID: 18388148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse.
    Cambridge G; Stohl W; Leandro MJ; Migone TS; Hilbert DM; Edwards JC
    Arthritis Rheum; 2006 Mar; 54(3):723-32. PubMed ID: 16508933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased tumor necrosis factor-alpha mRNA expression in whole blood from patients with rheumatoid arthritis: reduction after infliximab treatment does not predict response.
    Pachot A; Arnaud B; Marrote H; Cazalis MA; Diasparra J; Gouraud A; Mougin B; Miossec P
    J Rheumatol; 2007 Nov; 34(11):2158-61. PubMed ID: 17896807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis.
    Tan SM; Xu D; Roschke V; Perry JW; Arkfeld DG; Ehresmann GR; Migone TS; Hilbert DM; Stohl W
    Arthritis Rheum; 2003 Apr; 48(4):982-92. PubMed ID: 12687540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blockade of tumour necrosis factor-alpha in rheumatoid arthritis: effects on components of rheumatoid cachexia.
    Metsios GS; Stavropoulos-Kalinoglou A; Douglas KM; Koutedakis Y; Nevill AM; Panoulas VF; Kita M; Kitas GD
    Rheumatology (Oxford); 2007 Dec; 46(12):1824-7. PubMed ID: 18032540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations.
    Stohl W; Metyas S; Tan SM; Cheema GS; Oamar B; Xu D; Roschke V; Wu Y; Baker KP; Hilbert DM
    Arthritis Rheum; 2003 Dec; 48(12):3475-86. PubMed ID: 14673998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases.
    Cheema GS; Roschke V; Hilbert DM; Stohl W
    Arthritis Rheum; 2001 Jun; 44(6):1313-9. PubMed ID: 11407690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor.
    Rioja I; Hughes FJ; Sharp CH; Warnock LC; Montgomery DS; Akil M; Wilson AG; Binks MH; Dickson MC
    Arthritis Rheum; 2008 Aug; 58(8):2257-67. PubMed ID: 18668547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating tumour necrosis factor-alpha bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response.
    Marotte H; Maslinski W; Miossec P
    Arthritis Res Ther; 2005; 7(1):R149-55. PubMed ID: 15642135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aggressive periodontitis and chronic arthritis: blood mononuclear cell gene expression and plasma protein levels of cytokines and cytokine inhibitors.
    Sørensen LK; Havemose-Poulsen A; Bendtzen K; Holmstrup P
    J Periodontol; 2009 Feb; 80(2):282-9. PubMed ID: 19186969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peripheral blood expression of nuclear factor-kappab-regulated genes is associated with rheumatoid arthritis disease activity and responds differentially to anti-tumor necrosis factor-alpha versus methotrexate.
    Parker A; Izmailova ES; Narang J; Badola S; Le T; Roubenoff R; Ginsburg GS; Maier A; Coblyn JS; Shadick NA; Weinblatt ME
    J Rheumatol; 2007 Sep; 34(9):1817-22. PubMed ID: 17696278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis.
    Park MC; Chung SJ; Park YB; Lee SK
    Scand J Rheumatol; 2008; 37(3):173-8. PubMed ID: 18465450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mononuclear cell response to lipopolysaccharide in patients with rheumatoid arthritis: relationship with tristetraprolin expression.
    Fabris M; Tolusso B; Di Poi E; Tomietto P; Sacco S; Gremese E; Ferraccioli G
    J Rheumatol; 2005 Jun; 32(6):998-1005. PubMed ID: 15940758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The TTTT B lymphocyte stimulator promoter haplotype is associated with good response to rituximab therapy in seropositive rheumatoid arthritis resistant to tumor necrosis factor blockers.
    Fabris M; Quartuccio L; Vital E; Pontarini E; Salvin S; Fabro C; Zabotti A; Benucci M; Manfredi M; Ravagnani V; Biasi D; Atzeni F; Sarzi-Puttini P; Morassi P; Fischetti F; Bazzicchi L; Saracco M; Pellerito R; Cimmino M; Carraro V; Semeraro A; Schiavon F; Caporali R; Bortolotti R; Govoni M; Fogolari F; Tonutti E; Bombardieri S; Emery P; De Vita S
    Arthritis Rheum; 2013 Jan; 65(1):88-97. PubMed ID: 23001900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune complexes from rheumatoid arthritis synovial fluid induce FcgammaRIIa dependent and rheumatoid factor correlated production of tumour necrosis factor-alpha by peripheral blood mononuclear cells.
    Mathsson L; Lampa J; Mullazehi M; Rönnelid J
    Arthritis Res Ther; 2006; 8(3):R64. PubMed ID: 16569263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum levels of tumour necrosis factor family members a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BLyS) are inversely correlated in systemic lupus erythematosus.
    Morel J; Roubille C; Planelles L; Rocha C; Fernandez L; Lukas C; Hahne M; Combe B
    Ann Rheum Dis; 2009 Jun; 68(6):997-1002. PubMed ID: 18676986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of tristetraprolin (G0S24) mRNA, a regulator of tumor necrosis factor-alpha production, in synovial tissues of patients with rheumatoid arthritis.
    Tsutsumi A; Suzuki E; Adachi Y; Murata H; Goto D; Kojo S; Matsumoto I; Zhong L; Nakamura H; Sumida T
    J Rheumatol; 2004 Jun; 31(6):1044-9. PubMed ID: 15170914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutrophils of rheumatoid arthritis patients on anti-TNF-α therapy and in disease remission present reduced adhesive functions in association with decreased circulating neutrophil-attractant chemokine levels.
    Dominical VM; Bértolo MB; Almeida CB; Garrido VT; Miguel LI; Costa FF; Conran N
    Scand J Immunol; 2011 Apr; 73(4):309-18. PubMed ID: 21208248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.